https://imux.com imux Wed, 18 Feb 2026 14:48:56 +0000 hourly 1 https://wordpress.org/?v=6.9.4 https://imux.com/immunic-announces-oversubscribed-private-placement-of-up-to-usd-400-million-to-accelerate-transformation-into-commercial-stage-company/#comment-31 Wed, 18 Feb 2026 14:48:56 +0000 https://imux.com/?p=33488#comment-31 […] a phase 3 clinical program in PPMS,” Daniel Vitt, PhD, Immunic’s co-founder and CEO, said in a company press release. “We believe that now is the perfect time to prepare Immunic for its transformation into a highly […]

]]> https://imux.com/immunic-announces-vidofludimus-calcium-reduced-risk-of-disability-worsening-by-30-in-primary-progressive-multiple-sclerosis-patients-from-phase-2-calliper-trial/#comment-30 Fri, 23 May 2025 21:30:14 +0000 https://imux.com/?p=32520#comment-30 […] patients with PPMS, new evidence from Immunic’s Phase II CALLIPER trial showed some promise. The company’s oral therapy, vidofludimus calcium, activates the neuroprotective transcription […]

]]> https://imux.com/immunic-announces-vidofludimus-calcium-reduced-risk-of-disability-worsening-by-30-in-primary-progressive-multiple-sclerosis-patients-from-phase-2-calliper-trial/#comment-29 Thu, 01 May 2025 14:15:26 +0000 https://imux.com/?p=32520#comment-29 […] 1. https://imux.com/immunic-announces-vidofludimus-calcium-reduced-risk-of-disability-worsening-by-30-i… […]

]]> https://imux.com/immunic-announces-vidofludimus-calcium-reduced-risk-of-disability-worsening-by-30-in-primary-progressive-multiple-sclerosis-patients-from-phase-2-calliper-trial/#comment-28 Wed, 30 Apr 2025 22:21:14 +0000 https://imux.com/?p=32520#comment-28 […] Vidofludimus calcium, called IMU-838 by Immunic, showed only a “modest benefit” of 5% over placebo at improving the yearly rate of percent brain volume change in patients with PMS after the approximately two-year treatment period, Immunic said in an April 30 press release.  […]

]]> https://imux.com/immunic-presents-key-vidofludimus-calcium-data-at-the-40th-congress-of-ectrims-highlighting-its-therapeutic-potential-in-multiple-sclerosis/#comment-27 Thu, 09 Jan 2025 19:24:39 +0000 https://imux.com/?p=30883#comment-27 […] Interim data presented last year showed that vidofludimus calcium lowered levels of neurofilament light chain — a biomarker of nerve cell damage — after six months of treatment. That compared with increasing NfL levels over time among those given a placebo. The reductions were seen across MS types, age, and disability levels. […]

]]> https://imux.com/immunic-announces-positive-outcome-of-interim-analysis-of-phase-3-ensure-program-of-vidofludimus-calcium-in-relapsing-multiple-sclerosis/#comment-25 Mon, 04 Nov 2024 13:02:18 +0000 https://imux.com/?p=30917#comment-25 […] for relapsing and progressive MS. An interim section 3 evaluation of vidofludimus calcium revealed some constructive outcomes, and the corporate plans to launch extra section 2 information in April […]

]]> https://imux.com/immunic-announces-that-vidofludimus-calcium-acts-as-potent-nurr1-activator-reinforcing-neuroprotective-potential-in-multiple-sclerosis/#comment-24 Thu, 24 Oct 2024 08:15:05 +0000 http://iag-sv03.iagit.de/?p=28138#comment-24 […] calcium works by potently activating the neuroprotective transcription factor called nuclear receptor-related 1 (Nurr1), which is […]

]]> https://imux.com/immunic-inc-announces-private-placement-of-up-to-240-million/#comment-23 Thu, 15 Aug 2024 13:15:19 +0000 https://h3013233.stratoserver.net/imux-com/?p=29902#comment-23 […] January 2024, Immunic announced a private placement of up to $240 million. The company said these funds would be used to fund the ongoing clinical […]

]]> https://imux.com/immunic-announces-that-vidofludimus-calcium-acts-as-potent-nurr1-activator-reinforcing-neuroprotective-potential-in-multiple-sclerosis/#comment-22 Tue, 13 Aug 2024 17:37:41 +0000 http://iag-sv03.iagit.de/?p=28138#comment-22 […] Bidofludimus calcium activates target Null 1A neuroprotective transcription factor. Phase 3 Trials In relapsing MS, Phase 2 study Progressive […]

]]> https://imux.com/immunic-appoints-jason-tardio-as-chief-operating-officer-and-president/#comment-19 Wed, 10 Jul 2024 15:03:50 +0000 https://imux.com/?p=30658#comment-19 […] Therapeutic: “Immunic Appoints Jason Tardio as Chief Operating Officer and President” (July 9, […]

]]>